VISE Fall Seminar – Caroline Chung, MD
VISE Fall Seminar
to be led by
Caroline Chung, MD,
Assistant Professor of Radiation Oncology,
University of Texas MD Anderson Cancer Center
Date: Thursday, October 19, 2017
Location: Stevenson Center 5326
Time: 12:10 p.m. start, Noon lunch
“Personalizing radiotherapy for Cancer Care: The Next Frontier of Multidisciplinary Collaboration”
1. Review the evolution of radiotherapy planning and delivery and how it’s impacted clinical workflow and care
2. Provide an overview of approaches for personalizing radiotherapy and cancer care
3. Highlight opportunities for collaboration across scientific disciplines (radiation oncology, radiology, physics, engineering) to develop innovative technology-driven advances in cancer care.
Dr. Chung’s clinical practice includes the treatment of primary CNS malignancies, brain metastases and breast cancer. Her primary research interests have focused on personalized image-guided approaches for the management of brain tumors and metastases. Specifically, this includes the investigation of novel combinations of systemic therapy and radiosurgery for brain metastases and the evaluation of imaging biomarkers of both response and toxicity following treatment. With a translational approach, her preclinical work has included the investigation of conformal radiation in combination with targeted anti-angiogenic therapy in a murine intracranial brain tumor model with serial multiparametric MRI and biofluid measures to discover promising biomarkers of response to guide personalized treatment of brain tumors. The findings from this preclinical work has lead to several ongoing clinical trials evaluating serial MRI biomarkers in patients treated with radiosurgery as well as a Phase I dose-escalation trial of anti-angiogenic agent (Sunitinib) in concurrently with radiosurgery. In terms of image-guided therapy, Dr. Chung has also lead the early clinical evaluation of a novel image-guided Gamma Knife radiosurgery unit that incorporates cone-beam CT and infrared intrafraction motion-monitoring. In addition to tumor directed therapy, Dr. Chung is investigating imaging measures and potential treatments of radiation injury in the brain through her translational research and as the principal investigator of a multi-centred Phase II randomized clinical trial of bevacizumab + steroids vs. placebo + steroids through the Alliance for Clinical Trials in Oncology collaborative group.